These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27805978)

  • 1. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study.
    Englisch S; Jung HS; Lewien A; Becker A; Nowak U; Braun H; Thiem J; Eisenacher S; Meyer-Lindenberg A; Zink M
    J Clin Psychopharmacol; 2016 Dec; 36(6):597-607. PubMed ID: 27805978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agomelatine for Depression in Schizophrenia: A Case-Series.
    Mutschler J; Rüsch N; Schönfelder H; Herwig U; Brühl AB; Grosshans M; Rössler W; Russmann H
    Psychopharmacol Bull; 2012 Feb; 45(1):35-43. PubMed ID: 27738367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major depressive disorder, anhedonia and agomelatine: an open-label study.
    Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
    J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
    Olié JP; Kasper S
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of agomelatine in depression: the evidence.
    den Boer JA; Bosker FJ; Meesters Y
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S21-4. PubMed ID: 16436936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine, a melatonin agonist with antidepressant properties.
    Dubovsky SL; Warren C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonergic drugs in clinical practice.
    Hardeland R; Poeggeler B; Srinivasan V; Trakht I; Pandi-Perumal SR; Cardinali DP
    Arzneimittelforschung; 2008; 58(1):1-10. PubMed ID: 18368944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders].
    Lôo H; Daléry J; Macher JP; Payen A
    Encephale; 2002; 28(4):356-62. PubMed ID: 12232545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative-hypnotics on heart rate variability: Implications for cardiovascular risk.
    Chang CC; Tzeng NS; Yeh CB; Kuo TBJ; Huang SY; Chang HA
    World J Biol Psychiatry; 2018 Aug; 19(5):368-378. PubMed ID: 28281386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agomelatine treatment of major depressive disorder.
    Dolder CR; Nelson M; Snider M
    Ann Pharmacother; 2008 Dec; 42(12):1822-31. PubMed ID: 19033480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.
    Kennedy SH; Avedisova A; Giménez-Montesinos N; Belaïdi C; de Bodinat C;
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):553-63. PubMed ID: 24530273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agomelatine: efficacy at each phase of antidepressant treatment.
    Kennedy SH
    CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH Study.
    Englisch S; Jung HS; Eisenacher S; Lewien A; Becker A; Nowak U; Braun H; Thiem J; Meyer-Lindenberg A; Zink M
    J Clin Psychopharmacol; 2018 Aug; 38(4):357-361. PubMed ID: 29912792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agomelatine: innovative pharmacological approach in depression.
    Popoli M
    CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agomelatine in depression.
    Smeraldi E; Delmonte D
    Expert Opin Drug Saf; 2013 Nov; 12(6):873-80. PubMed ID: 24033095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review.
    Pompili M; Serafini G; Innamorati M; Venturini P; Fusar-Poli P; Sher L; Amore M; Girardi P
    World J Biol Psychiatry; 2013 Aug; 14(6):412-31. PubMed ID: 23530731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating each and every depressed patient.
    Kennedy SH
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.